Htr2B Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| HTR2B | |
|---|---|
| Full Name | 5-Hydroxytryptamine Receptor 2B |
| Chromosome | 2q36.3 |
| NCBI Gene ID | 3351 |
| OMIM | 601122 |
| Ensembl ID | ENSG00000180264 |
| UniProt ID | Q9H3Y9 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Migraine, Pulmonary Hypertension |
The serotonin 2B receptor (5-HT2B) is a G protein-coupled receptor that primarily couples to Gq proteins, activating phospholipase C and leading to increased intracellular calcium. In the brain, 5-HT2B is expressed in the cortex, hippocampus, and basal ganglia. It plays roles in mood regulation, anxiety, and memory. Dysregulation of 5-HT2B signaling has been implicated in neurodegenerative processes through effects on neuroinflammation, neurogenesis, and synaptic plasticity. Animal studies suggest that 5-HT2B modulation may have therapeutic potential in Alzheimer's and Parkinson's diseases.
The HTR2B gene is located on chromosome 2q36.3 and consists of 13 exons spanning approximately 16 kb. The gene encodes a protein of 481 amino acids with the characteristic seven-transmembrane domain structure of GPCRs. The promoter region contains binding sites for multiple transcription factors including SP1, AP-2, and CREB, allowing for tissue-specific expression and regulation.
The 5-HT2B receptor is a Class A GPCR with:
In the central nervous system, 5-HT2B is expressed in:
Peripheral expression includes:
5-HT2B receptor signaling involves:
In neurons, 5-HT2B:
5-HT2B signaling affects amyloid-beta (Aβ) metabolism and neuroinflammation. Studies show that 5-HT2B activation can:
Therapeutic targeting with 5-HT2B antagonists may reduce Aβ pathology.
5-HT2B receptors are upregulated in PD brains and may contribute to:
5-HT2B antagonists show promise in reducing levodopa-induced dyskinesias.
5-HT2B is implicated in the trigeminovascular system for migraine pain. Triptans (5-HT1B/1D agonists) may also act indirectly on 5-HT2B.
5-HT2B overexpression contributes to pulmonary vascular remodeling. FDA-approved antagonists (terguride, selexipag) are used clinically.
The study of Htr2B Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.